Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 24, 2026, NanoViricides, Inc. (the “Company”) and a certain purchaser (the “Investor”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investor in a registered direct offering (the “Offering”): (i) 2,416,339 shares of common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $1.53 per s…

Entry into a Material Definitive Agreement. On July 17, 2026, NanoViricides, Inc., a Delaware corporation (the “Company”), entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with D. Boral Capital LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agent, shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), in an “at the market” offering as defined in Rule 415(a)(4) und…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On May 15, 2026, NanoViricides, Inc. (the “Company”) and a certain purchaser (the “Investor”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investor in a registered direct offering (the “Offering”): (i) 1,133,334 shares of common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $1.50 per sh…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On November 10, 2025, NanoViricides, Inc. (the “Company”) and a certain institutional investor (the “Investor”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investor in a registered direct offering (the “Registered Direct Offering”): (i) 1,970,000 shares of common stock, par value $0.00001 per share (the “Common Stock”),…

Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.

The filing details the extension of employment agreements for Dr. Anil Diwan and Meeta Vyas, with no indication of a departure or significant change in roles.

The filing details extensions to existing employment agreements for Dr. Anil Diwan and Meeta Vyas, with no significant change in their roles or status.

Entry into a Material Definitive Agreement. As previously reported, on July 31, 2020, the Company entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. and Kingswood Capital Markets, a division of Benchmark Investments, Inc. (now EF Hutton LLC) (each a “Sales Agent” and collectively, the “Sales Agents”), pursuant to which we may offer and sell, from time to time, through or to the Sales Agents, shares of common stock (the “Placement Shares”), having an aggregate of…

Entry into a Material Definitive Agreement. On March 27, 2023, NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Karveer Meditech Private Limited (“Karveer”) whereby NanoViricides granted to Karveer a limited, non-transferable, exclusive license for the development and commercialization and further use, sale, or offer of sale of the Licensed Product(s) NV-CoV-2 and NV-CoV-2-R (the “Two Clinical Test Drug Candidates”) in the Territory of India, and as…

Entry into Material Definitive Agreements. On September 9, 2021, NanoViricides, Inc. (the “Registrant”) entered into a License Agreement (the “Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Registrant for further development with respect to TheraCour’s research and development of services with respect to treatments for coronavirus derived human infections. The Registrant was not required to make any upfront cash payments to TheraCour and agree…

Dr. Anil R. Diwan: The filing details an extension and modification of Dr. Diwan's existing employment agreement, including compensation and benefits.

Director — Brian Zucker: Appointment of Brian Zucker as a new member of the Board of Directors.